These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 28585595)

  • 1. Treatment of chronic Hepatitis C in Thalassemia major patients.
    Sajjad SF; Ahmad W; Hussain Jaffery SS; Asif M; Alam SE
    J Pak Med Assoc; 2017 Jun; 67(6):926-928. PubMed ID: 28585595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early predictability of virological response in patients of chronic hepatitis-C with genotype-3, treated with pegylated interferon and ribavirin.
    Umar M; Khaar HU; Khan SA; Ahmed M; Ambreen S; Minhas ZM; Nazar M
    J Ayub Med Coll Abbottabad; 2014; 26(4):559-63. PubMed ID: 25672187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
    Merli M; Giannelli V; Gentili F; Giusto M; Simmaco M; Lionetto L; Corradini SG; Biliotti E; Attili AF; Rossi M; Taliani G
    Antivir Ther; 2011; 16(6):879-85. PubMed ID: 21900720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.
    Li CK; Chan PK; Ling SC; Ha SY
    Br J Haematol; 2002 Jun; 117(3):755-8. PubMed ID: 12028054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PREDICTIVE VALUE OF EARLY VIRIOLOGICAL RESPONSE FOR SUSTAINED VIRIOLOGICAL RESPONSE IN CHRONIC HEPATITIS WITH CONVENTIONAL INTERFERON THERAPY.
    Awan A; Umar M; Khaar Ht; Kulsoom A; Minhas Z; Ambreen S; Habib N; Mumtaz W; Habib F
    J Ayub Med Coll Abbottabad; 2016; 28(1):14-7. PubMed ID: 27323553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB; Atabay A; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
    Baiocchi L; De Leonardis F; Delle Monache M; Nosotti L; Conti RL; Lenci I; Carbone M; Di Paolo D; Cucchiarelli S; Angelico M
    Antivir Ther; 2010; 15(4):633-9. PubMed ID: 20587856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.
    Oh IS; Won JW; Kim HJ; Lee HW
    Korean J Intern Med; 2017 Nov; 32(6):1010-1017. PubMed ID: 28797159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.